Double-Masked, Randomized, Phase 2 Evaluation of Abicipar Pegol (An Anti-Vegf DARPin Therapeutic) in Neovascular Age-Related Macular Degeneration

Journal of Ocular Pharmacology and Therapeutics - United States
doi 10.1089/jop.2018.0062
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Mary Ann Liebert Inc

Related search

Dual Antagonism of PDGF and VEGF in Neovascular Age-Related Macular Degeneration

Ophthalmology
Ophthalmology
2017English

An Evaluation of Photographic Screening for Neovascular Age-Related Macular Degeneration

Eye
MedicineArtsSensory SystemsOphthalmologyHumanities
2005English

Macular Atrophy in Neovascular Age Related Macular Degeneration

Journal of Clinical Review & Case Reports
2019English

Common Variant in VEGFA and Response to Anti-Vegf Therapy for Neovascular Age-Related Macular Degeneration

Current Molecular Medicine
BiochemistryMedicineMolecular MedicineMolecular Biology
2013English

IL-18 Is Not Therapeutic for Neovascular Age-Related Macular Degeneration

Nature Medicine
BiochemistryMedicineGeneticsMolecular Biology
2014English

Aflibercept for Neovascular Age-Related Macular Degeneration

Cochrane Database of Systematic Reviews
2016English

Role of Interleukin 33 in Neovascular Age-Related Macular Degeneration

The Lancet
Medicine
2016English

Ranibizumab Versus Verteporfin for Neovascular Age-Related Macular Degeneration

New England Journal of Medicine
Medicine
2006English

Treatment of Age-Related Neovascular Macular Degeneration: The Patient’s Perspective

Graefe's Archive for Clinical and Experimental Ophthalmology
Molecular NeuroscienceOphthalmologySensory SystemsCellular
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy